Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Reuters and First Call Consensus ratings
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Reuters and First Call Consensus ratings

posted on Mar 02, 2009 09:23AM

Can anyone verify (from a source other than Vanguard) Reuters rating of PTSC?

The message today through my Vanguard account web site is "PTSC not covered by Reuters." If this is true Reuters has been vacillating between "Outperform" and "Not Covered".

First Call Consensus continues to rate PTSC as a Strong Buy, with one analyst reporting.



1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply